Table 2.
Primary malignancy in 1280 patients with 1348 TIVADs for long-term intravenous chemotherapy n (%)
| Malignancy | Patients | TIVADs |
| Colorectal | 354 (27.7) | 359 (26.6) |
| Lung | 348 (27.2) | 367 (27.2) |
| Head and Neck | 139 (10.8) | 150 (11.1) |
| Breast | 103 (8.0) | 109 (8.1) |
| Gastric | 78 (6.1) | 91 (6.8) |
| Hematogenous | 70 (5.5) | 76 (5.6) |
| H-B-P | 69 (5.5) | 72 (5.4) |
| Esophageal | 41 (3.2) | 43 (3.2) |
| Urologic | 40 (3.1) | 40 (3.0) |
| Gynecologic | 12 (0.9) | 14 (1.0) |
| Others1 | 26 (2.0) | 27 (2.0) |
| Total | 1280 (100) | 1348 (100) |
1
Others include skin, brain, bone, sarcoma and unknown primary origin. H-B-P: Hepato-biliary-pancreatic.